Comparison Of Short-term Efficacy Between Conbercept And Ranibizumab For The Treatment Of Myopic Neovascularization

Purpose:To evaluate the short-term efficacy of conbercept compared to ranibizumab for the treatment of myopic choroidal neovascularization(mCNV).Method:This was a retrospective and comparative study.Between September 2013 and September 2018,43 patients were received intravitreal conbercep or ranibizumab.Patients were administered either conbercept 0.5mg or ranibizumab 0.5mg basing on a1+PRN(Pro Re Nata)protocol and followed up for 6 months.Primary outcomes include best-corrected visual acuity(BCVA),central foveal thickness(CFT)and area of CNV lesion before and 1,3,6 months after the initial treatment and total number of injections as well as adverse effects from treatment.Results:In the conbercept group,the mean BCVA improved to logMAR(0.67±0.56),logMAR(0.58±0.42)and logMAR(0.54±0.40)at 1,3,6 months after injection compared with the baseline BCVA,the mean CFT declined to 284.2±125.0μm,258.0±106.1μm and 245.1±80.2μm at 1,3,6 months,the mean CNV area decreased to 1.15±0.72 mm~2,0.95±0.71 mm~2 and 0.86±0.66 mm~2 at 1,3,6 months after administration.In the ranibizumab group,the mean BCVA increased to logMAR(0.59±0.47),logMAR(0.54±0.44)and logMAR(0.51±0.46),the mean CFT reduced to 267.3±105.1μm,232.1±81.1μm and 223.2±78.5μm and the mean CNV area changed to 0.90±0.68mm~2,0.70±0.64mm~2 and 0.61±0.62mm~2 at 1,3,6 months respectively after intravitreal ranibizumab.All P<0.05 in comparison with the preoperative measures in each group.The BCVA improvement between the two groups were comparable at the same follow-up time point from treatment(all P>0.05).At 1 month after the initial injection,there were statistically significant differences in CFT reduction and CNV area decrease between the two drugs(P=0.015 and P=0.007).As for the mean number of injections,conbercept group was less than ranibizumab group(P=0.002).Neither ocular nor systemetic safety problems appeared during follow up.Conclusions:Intravitreal cnonbercept and ranibizumab are both safe.The study showed a similar functional and anatomical improvement after treatment of conbercept and ranibizumab for myopic CNV during a 6-month follow-up period,but conbercept may be more effective than ranibizumab in promoting CFT and CNV lesion reduction in a short period and it may have a fewer injections than ranibizumab.